Sanofi Secures US Approval for Type 3 Gaucher Disease Treatment
Sanofi said it received US approval for the first treatment targeting neurological symptoms of Type 3 Gaucher disease.
Sanofi said it received US approval for the first treatment targeting neurological symptoms of Type 3 Gaucher disease.